Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Ascendis Pharma A/S ASND
$94.93
-$0.96 (-1.01%)
На 18:00, 12 мая 2023
+77.68%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
5398364862.00000000
-
week52high
134.53
-
week52low
61.58
-
Revenue
51174000
-
P/E TTM
-8
-
Beta
0.54636600
-
EPS
-10.38000000
-
Last Dividend
0.00000000
-
Next Earnings Date
27 апр 2023 г. в 20:30
Описание компании
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 11 авг 2022 г. |
| Oppenheimer | Outperform | Outperform | 11 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 11 авг 2022 г. |
| Wells Fargo | Overweight | Overweight | 12 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 12 мая 2022 г. |
| Wells Fargo | Overweight | Overweight | 22 сент 2022 г. |
| Goldman Sachs | Buy | 20 окт 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 03 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 03 ноя 2022 г. |
| Citigroup | Buy | Buy | 03 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 15 ноя 2022 г. |
| Wedbush | Outperform | Outperform | 14 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 14 ноя 2022 г. |
| Wells Fargo | Overweight | Overweight | 07 ноя 2022 г. |
| Wells Fargo | Overweight | Overweight | 03 янв 2023 г. |
| SVB Leerink | Outperform | Outperform | 17 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Ascendis Pharma shares pop after FDA rejects hormone therapy application but not the underlying clinical data
Proactive Investors
01 мая 2023 г. в 13:57
The US Food and Drug Administration (FDA) did not grant its approval to Ascendis Pharma's experimental hormone disorder therapy, but the company's stock has soared Monday nonetheless. The therapy, called TransCon OTH, is designed to treat adult patients with a disorder called hypoparathyroidism, in which the body produces abnormally low levels of parathyroid hormone.
Why Shares of Ascendis Pharma Are Climbing Monday
The Motley Fool
01 мая 2023 г. в 11:45
Ascendis has seen a big uptake in sales for its human growth hormone therapy. The company said it plans to request a meeting with the FDA regarding hyperthyroidism therapy TransCon PTH.
Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript
Seeking Alpha
27 апр 2023 г. в 22:34
Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript.
These Are the Top 10 Holdings of Avoro Capital Advisors
24/7 Wall Street
17 апр 2023 г. в 22:54
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
Ascendis Pharma: Recent FDA Setbacks Present A Buying Opportunity
Seeking Alpha
16 апр 2023 г. в 22:56
We are upgrading from a hold to buy rating for ASND following a 35% drop in stock price after FDA deficiency findings in the NDA for TransCon PTH for hyperparathyroidism. We expect potential US FDA approval delays beyond the April 30 PDUFA date but an eventual approval.